Navigation Links
Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
Date:9/3/2008

of the open-label, large sample, multi-center Endu phase IV clinical study affirms the safety and therapeutic efficacy of Endu acting in conjunction with platinum-based chemotherapy. With our continued research of Endu Phase IV, we will collect more clinical data to further evaluate the safety and efficacy of Endu."

To date, over 2,000 NSCLC patients have been recruited for Endu Phase IV clinical study. The final results of the study will be announced in the first half of 2010.

As a leading patented anti-cancer biotech product in China, Endu is recommended in the National Comprehensive Cancer Network of China Clinical Practice Guidelines in Oncology Chinese Version (2006-2008)as a first line treatment for NSCLC.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has been focusing its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmac
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
2. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
3. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
4. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
5. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
6. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
7. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
8. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
11. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... -- Biomedical Research Laboratories (BRL) ( www.brlscience.com ) announced ... 2014 Inc. 500 list of America,s fastest-growing companies. ... prestigious list and ranked among the most successful companies ... Laboratories, CEO. "Today,s announcement represents a major milestone for ... work and talent of our team. BRL has a ...
(Date:8/26/2014)... Mass. , Aug. 26, 2014 Acelleron Medical ... Eatontown, N.J ., is expanding.  Acelleron, a ... to form a new division, Acelleron Maternal Health & Wellness ... clients by providing a full range of resources for pregnant ... has been named the director of maternal wellness. Vecchi, the ...
(Date:8/26/2014)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and its associated pain, ... advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) ... more than 100,000 Americans. As this disease progresses, ... lose the ability to breathe, leading ultimately to ...
Breaking Medicine Technology:Biomedical Research Laboratories Named to Inc. 500 List of America's Fastest-Growing Companies 2Suzanne Vecchi Named Director of Newly Acquired Acelleron Maternal Health & Wellness 2Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 2Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 3
... DATATRAK International, Inc. (OTCQX: DATA), a technology and services ... trials industry, today announced that it has been awarded ... Organization (CRO) in India, with which the Company had ... order to execute a Phase II study for the ...
... 8, 2011 Vanda Pharmaceuticals Inc. (Nasdaq: ... has granted orphan drug designation for tasimelteon, an oral ... for Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals with ... the designation that the Committee for Orphan Medicinal Products ...
Cached Medicine Technology:DATATRAK Awarded First Study With Kreara Solutions 2DATATRAK Awarded First Study With Kreara Solutions 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 2Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 4
(Date:8/26/2014)... Hearing aids are not always covered ... holders to determine what their hearing care benefits are. ... health plans and has published benefit details on their website ... , The following is a list of insurances or agencies ... NYSHIP/ NYS Empire Plan - Hearing Aid Benefit is $1500 ...
(Date:8/26/2014)... August 27, 2014 Emerging and established ... and useful to those they serve – which includes ... blog at http://www.PerWickstrom.com and read his latest ... Leaders Maintain their Edge.” , “Leadership is ... and can therefore be assumed,” commented Per Wickstrom, who ...
(Date:8/26/2014)... August 27, 2014 There are a ... however the reality is cruel. Some people, especially ladies ... may not save enough money to be affluent. Today, ... delighted to announce its new catalog, Flash Deals (also ... bags, outdoor accessories and more from this company are ...
(Date:8/26/2014)... 27, 2014 Atlanta Hearing Associates ... Hearing Associates has expanded its professional staff to 6 audiologists. ... Stephanie Collins . Atlanta Hearing Associates prides itself ... display a passionate commitment to patient needs and keep themselves ... loss treatments. The practice has grown from 1 to 4 ...
(Date:8/26/2014)... (PRWEB) August 27, 2014 Private ... custom labeled nutritional dietary supplements and products has ... their 33rd annual Inc. 500|5000 list. This exclusive ... marks the second consecutive year for Private Label ... Dell, Yelp, GoPro, Bridger, Tough Mudder, Bowlmor and ...
Breaking Medicine News(10 mins):Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 2Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 3Health News:Per Wickstrom’s Latest Blog Post Provides 10 Tips to Help Leaders Maintain their Edge 2Health News:Become a Rich Person Right Away By Taking Advantage Of Fecbek.com's Flash Deals 2Health News:Atlanta Hearing Associates Needs New Audiologists to Its Professional Staff 2Health News:Atlanta Hearing Associates Needs New Audiologists to Its Professional Staff 3Health News:Private Label Nutraceuticals Honored by Inc. 5000 as One of Today’s Fastest Growing Private Companies in America with Three-Year Sales Growth of 620% 2Health News:Private Label Nutraceuticals Honored by Inc. 5000 as One of Today’s Fastest Growing Private Companies in America with Three-Year Sales Growth of 620% 3Health News:Private Label Nutraceuticals Honored by Inc. 5000 as One of Today’s Fastest Growing Private Companies in America with Three-Year Sales Growth of 620% 4
... poses dangers, researchers say , , TUESDAY, Dec. 23 (HealthDay ... adults in the United States combine over-the-counter medications with ... for potentially dangerous interactions, a new survey finds. , ... for more than 175,000 emergency department visits for adverse ...
... doesn,t fund procedure , , TUESDAY, Dec. 23 (HealthDay ... each year, because their states don,t cover the procedure ... case to be made that circumcisions can protect our ... of public policy at the University of California, Los ...
... major tissue damage or surgical intervention is an important ... established therapeutic measure for severe liver diseases, it would ... the regenerative process and if they depend on the ... The group led by Prof. Schlaak from the Department ...
... It might be possible to grow human blood ... new study at The Ohio State University Medical Center. ... issue of the journal Experimental Hematology , might ... and in quantities that can ease the chronically tight ...
... the mutation faced higher odds of heart attack, death, study ... variation can make younger heart attack patients more prone to ... receive the anti-clotting drug Plavix, researchers report. , The study ... The Lancet . , Plavix plus low-dose aspirin are often ...
... LANSING, Mich. Only 3 percent of kids, meals ... the first study to examine the nutrient quality of ... Michigan State University,s Sharon Hoerr, a food science and ... teamed up with economist Sharon O,Donnell and pediatrician Jason ...
Cached Medicine News:Health News:Drug Combinations Putting Seniors at Risk 2Health News:Drug Combinations Putting Seniors at Risk 3Health News:Drug Combinations Putting Seniors at Risk 4Health News:Circumcision Rates Too Low 2Health News:Molecular events involved in liver regeneration 2Health News:Bioreactors might solve blood-platelet supply problems 2Health News:Gene Ups Risk for Those on Blood-Thinner Plavix 2Health News:Gene Ups Risk for Those on Blood-Thinner Plavix 3Health News:Nutritious fast-food kids' meals are scarce, researchers find 2
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The CA method used on the Dade Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of calcium in serum....
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
Medicine Products: